Feb 6 2019


“The authors are very grateful to Dr. Emilien Dosda, Dr. Xavier Rousset and Sylvain Roveda

from Inovotion for their work on the CAM study.”  SpringerLink


Genoscience Pharma a clinical stage biotech focused on Oncology, conducted research on GNS561, a

lysosomotropic molecule they developed. With the help of INOVOTION’s chick embryo model, the team

could confirm the anticancer activity of their molecule against intrahepatic cholangiocarcinoma and

published their results on February 20, 2019.

Once INOVOTION started the study on GNS561, Genoscience Pharma received the in vivo results for

their research within 1 month and could publish this article only 10 months later. Supported by GNS561

efficacy in in vivo models (chicken embryo, rats and mice animals models), Genoscience Pharma is

currently assessing GNS561’s safety and efficacy through an international Phase1b/2a clinical trial in

liver cancer.


GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma


If you too are interested in optimizing your preclinical drug discovery with our powerful

in vivo technology platform, please contact us for a free estimate! 


If you wish to discover more example of Inovotion’s client publications in the best peer

reviewed journals.

All our news

All our webinars